Androgen axis in prostate cancer.

@article{Culig2006AndrogenAI,
  title={Androgen axis in prostate cancer.},
  author={Zoran Culig and Georg Bartsch},
  journal={Journal of cellular biochemistry},
  year={2006},
  volume={99 2},
  pages={373-81}
}
Endocrine therapy for advanced prostate cancer is based on androgen ablation or blockade of the androgen receptor (AR). AR action in prostate cancer has been investigated in a number of cell lines, their derivatives, and transgenic animals. AR expression is heterogenous in prostate cancer in vivo; it could be detected in most primary tumors and their metastases. However, some cells lack the AR because of epigenetic changes in the gene promoter. AR expression increases after chronic androgen… CONTINUE READING